Compare Fulford India with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs TORRENT PHARMA - Comparison Results

FULFORD INDIA     Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA TORRENT PHARMA FULFORD INDIA/
TORRENT PHARMA
 
P/E (TTM) x 398.8 53.2 749.5% View Chart
P/BV x 6.2 6.4 97.5% View Chart
Dividend Yield % 0.1 0.8 10.5%  

Financials

 FULFORD INDIA   TORRENT PHARMA
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
TORRENT PHARMA
Mar-18
FULFORD INDIA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs9421,550 60.8%   
Low Rs4501,144 39.4%   
Sales per share (Unadj.) Rs691.4354.7 194.9%  
Earnings per share (Unadj.) Rs11.540.1 28.6%  
Cash flow per share (Unadj.) Rs15.464.2 23.9%  
Dividends per share (Unadj.) Rs2.0014.00 14.3%  
Dividend yield (eoy) %0.31.0 27.6%  
Book value per share (Unadj.) Rs380.0273.1 139.1%  
Shares outstanding (eoy) m3.90169.22 2.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.03.8 26.5%   
Avg P/E ratio x60.733.6 180.7%  
P/CF ratio (eoy) x45.321.0 216.1%  
Price / Book Value ratio x1.84.9 37.1%  
Dividend payout %17.434.9 49.9%   
Avg Mkt Cap Rs m2,714227,897 1.2%   
No. of employees `0000.414.7 3.0%   
Total wages/salary Rs m50511,353 4.4%   
Avg. sales/employee Rs Th6,073.04,083.0 148.7%   
Avg. wages/employee Rs Th1,137.4772.3 147.3%   
Avg. net profit/employee Rs Th100.7461.3 21.8%   
INCOME DATA
Net Sales Rs m2,69660,021 4.5%  
Other income Rs m1252,988 4.2%   
Total revenues Rs m2,82263,009 4.5%   
Gross profit Rs m-4613,493 -0.3%  
Depreciation Rs m154,086 0.4%   
Interest Rs m103,085 0.3%   
Profit before tax Rs m549,310 0.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m102,529 0.4%   
Profit after tax Rs m456,781 0.7%  
Gross profit margin %-1.722.5 -7.7%  
Effective tax rate %17.727.2 65.1%   
Net profit margin %1.711.3 14.7%  
BALANCE SHEET DATA
Current assets Rs m1,73852,623 3.3%   
Current liabilities Rs m54552,022 1.0%   
Net working cap to sales %44.31.0 4,417.1%  
Current ratio x3.21.0 315.5%  
Inventory Days Days48120 40.5%  
Debtors Days Days476 5.6%  
Net fixed assets Rs m1285,016 0.0%   
Share capital Rs m39846 4.6%   
"Free" reserves Rs m1,44345,376 3.2%   
Net worth Rs m1,48246,222 3.2%   
Long term debt Rs m041,115 0.0%   
Total assets Rs m2,077142,432 1.5%  
Interest coverage x6.74.0 167.1%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x1.30.4 308.1%   
Return on assets %2.66.9 37.7%  
Return on equity %3.014.7 20.6%  
Return on capital %4.314.2 30.3%  
Exports to sales %00-   
Imports to sales %24.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m659NA-   
Fx inflow Rs m1714,580 0.1%   
Fx outflow Rs m6733,600 18.7%   
Net fx Rs m-65610,980 -6.0%   
CASH FLOW
From Operations Rs m908,942 1.0%  
From Investments Rs m105-47,070 -0.2%  
From Financial Activity Rs m-1434,174 -0.0%  
Net Cashflow Rs m181-3,655 -4.9%  

Share Holding

Indian Promoters % 0.0 71.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.8 7.0 54.1%  
FIIs % 0.1 12.6 0.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 8.8 240.9%  
Shareholders   4,783 26,511 18.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   STERLING BIOTECH  PFIZER  ALEMBIC PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  

Compare FULFORD INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 181 Points Higher; Energy and Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours but ended their session off day's high.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA 5-YR ANALYSIS

COMPARE FULFORD INDIA WITH

MARKET STATS